Pharmacokinetic-Pharmacodynamic Relationship of Piretanide in Healthy and Uremic Subjects

REFERENCES

• Allison ME, Keenedy AE. Diuretics in chronic renal disease. A study of high dosage furosemide. Clin Sci 1971; 41: 171–187.
   PubMed Web of Science ®Google Scholar
• Baylis PH, De Beer FC. Human plasma vasopressin response to potent loop-diuretic drugs. Eur J Clin Pharmacol 1981; 20: 343–346.
   PubMed Web of Science ®Google Scholar
• Beermann B, Dahlén E, Lindström B. Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 1977; 22: 70–78.
   PubMed Web of Science ®Google Scholar
• Beermann B, Odlind B, Wibell L. Diuretic effect and pharmacokinetics of tizolemide in subjects with normal and decreased renal function. Clin Nephrol 1983; 19: 124–131.
   PubMed Web of Science ®Google Scholar
• Berg KJ, Tromsdal A, Wideroe T-E. Diuretic action of bumetanide in advanced chronic renal insufficiency. Eur J Clin Pharmacol 1976; 265–275.
   Google Scholar
• Berg KJ, Walstad RA, Bergh K. The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. Br J Clin Pharmacol 1983; 15: 347–353.
   PubMed Web of Science ®Google Scholar
• Bogie W, Homeida M, Roberts CJC, Roberts F. Relationship between urate retention and electrolyte excretion during treatment with loop diuretics. Proc Br Pharmacol Soc 1977, March 30–31, App 20: 25.
   Google Scholar
• Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: Shift in dose–response curves. Clin Pharmacol Ther 1980; 28: 182–186.
   PubMed Web of Science ®Google Scholar
• Brater DC, Anderson S, Baird B, Kaojarern S. Effects of piretanide in normal subjects. Clin Pharmacol Ther 1983; 34: 324–330.
   PubMed Web of Science ®Google Scholar
• Brazier JL, Pozet N, Faucon G, Traeger J, Hadj-Aissa A. Kinetics of a high dose of piretanide in renal failure. Eur J Clin Pharmacol 1982; 21: 307–310.
   PubMed Web of Science ®Google Scholar
• Brooks BA, Lant AF. The use of the human erythrocyte as a model for studying the action of diuretics on sodium and chloride transport. Clin Sci Molec Med 1978; 54: 679–683.
   PubMedGoogle Scholar
• Candia OA, Schoen HF, Low L, Podos SM. Chloride transport inhibition by piretanide and MK-196 in bullfrog corneal epithelium. Am J Physiol 1981; 240: F25–F29.
   PubMedGoogle Scholar
• Casco C, Fainstein Day P, Mautalen C. The acute effects of piretanide upon serum and urinary calcium in normal subjects. Henry Ford Hosp Med J 1980; 28: 127–131.
   PubMedGoogle Scholar
• Dal Canton A, Russo D, Gallo R, Conte G, Andreucci VE. Muzolimine: a new high-ceiling diuretic suitable for patients with advanced renal disease. Br Med J 1981; 282: 595–598.
   PubMed Web of Science ®Google Scholar
• Edwards KDG, Sinnett PF, Stewart JH. Ethacrynic acid: assessment of saluretic and diuretic potency in patients with severe chronic renal failure. Med J Aust 1967; 54: 375–381.
   Google Scholar
• Eveloff J, Bayerdorfer E, Silva P, Kinne R. Sodiumchloride transport in the thick ascending limb of Henle's loop. Pflügers Arch 1981; 389: 263–270.
   PubMed Web of Science ®Google Scholar
• George CRP. Piretanide: effective diuretic in renal failure. Med J Aust 1981; 1: 83–84.
   PubMed Web of Science ®Google Scholar
• Greger R, Schlatter E. Cellular mechanism of the action of loop diuretics on the thick ascending limb of Henle's loop. Klin Wochenschr 1983; 61: 1019–1027.
   PubMedGoogle Scholar
• Hadj Aissa A, Pozet N, Labeeuw M, Pellet M, Traeger J. Acute effect of a high dose (48 mg) of piretanide in advanced renal insufficiency. Br J Clin Pharmacol 1981; 1: 63–68.
   Google Scholar
• Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modelling. J Pharmacol Exp Ther 1985; 233: 447–453.
   PubMed Web of Science ®Google Scholar
• Henderson IS, Beattie TJ, Kennedy AC, Dombey SL. Oral piretanide in chronic renal failure. Br J Clin Pharmacol 1982; 14: 857–860.
   PubMed Web of Science ®Google Scholar
• Heptner W, Baudner S, Dagrosa EE, Hellstern C, Irmisch R, Strecker H, Wissman H. A radioimmunoassay to measure piretanide in human serum and urine. J Immunoassay 1984; 5: 13–27.
   PubMed Web of Science ®Google Scholar
• Kampf VD, Baethke R. Die diuretische Effektivitat von Bumetanid im kontrollierten Vergleich zu Furosemid bei chronischer Niereninsuffizienz unterschiedlich Schweregrades. Arzneim Forsch 1980; 30: 1015–1018.
   PubMedGoogle Scholar
• Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine is an independent determinant of overall response. Kidney Int 1982; 22: 69–74.
   PubMed Web of Science ®Google Scholar
• Lawrence JR, Ansari AF, Elliott HL, Summer DJ, Brunton GF, Whiting B, Whitesmith R. Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther 1978; 23: 558–565.
   PubMed Web of Science ®Google Scholar
• Leary WP, Reeyes AJ, Venter CP, Blake GTW. Mathematical description of diuresis after oral administration of piretanide, furosemide and placebo to healthy adults. Curr Ther Res 1981; 29: 249–252.
   Web of Science ®Google Scholar
• Marone C, Reubi FC. Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanism in patients with the nephrotic syndrome. Eur J Clin Pharmacol 1980; 17: 165–171.
   PubMed Web of Science ®Google Scholar
• Marone C, Reubi FC, Lahn W. Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency. Eur J Clin Pharmacol 1984; 26: 413–418.
   PubMed Web of Science ®Google Scholar
• Merkel W, Bormann D, Mania D, Muschaweck R, Hropot M. Piretanide (HOE 118) a new high ceiling salidiuretic. Eur J Med Chem 1976; 11: 399–406.
   Web of Science ®Google Scholar
• Odlind B. Relation between renal tubular secretion and effects of five loop diuretics. J Pharmacol Exp Ther 1979; 211: 238–244.
   PubMed Web of Science ®Google Scholar
• Odlind B, Beermann B, Setén G, Persson AEG. Renal tubular secretion of piretanide and its effects on electrolyte reabsorption and tubuloglomerular feedback mechanism. J Pharmacol Exp Ther 1983; 225: 742–746.
   PubMed Web of Science ®Google Scholar
• Pillay VKG, Schwartz FC, Aimi K. Transient and permanent deafness following treatment with ethacrynic acid in renal failure. Lancet 1961; i: 77–81.
   Google Scholar
• Pozet N, Hadj-Aissa A, Pellet M. Activity of a new high efficiency diuretic in man: Piretanide (HOE 118). Br J Clin Pharmacol 1980; 9: 577–583.
   PubMed Web of Science ®Google Scholar
• Rane A, Villeneuve IP, Stone WI, Nies AS, Wilkinson GR, Branch RA. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 1978; 24: 199–207.
   PubMed Web of Science ®Google Scholar
• Reyes AM, Leary WP, Venter CP. Mathematical evaluation of the effects of piretanide, furosemide and placebo in healthy adults. Curr Ther Res 1981; 29: 253–257.
   Web of Science ®Google Scholar
• Roberts CJC, Homeida M, Roberts F. Effects of piretanide, bumetanide and furosemide on electrolyte and urate excretion in normal subjects. Br J Clin Pharmacol 1978; 6: 129–133.
   PubMed Web of Science ®Google Scholar
• Rupp W. Pharmacokinetics and pharmacodynamics of Lasix. Scot Med J 1974; 19: 5–12.
   PubMed Web of Science ®Google Scholar
• Teredesal P, Puschett JB. Acute effects of piretanide in normal subjects. Clin Pharmacol Ther 1979; 25: 331–339.
   PubMed Web of Science ®Google Scholar
• Winaver J, Sylk DB, Teredesal PR, Robertson JS, Puschett JB. Dissociative effects of piretanide on proximal tubular PO4 and HCO3 transport. Am J Physiol 1980; 238: F60–F68.
   PubMedGoogle Scholar
• Zeuthen T, Ramos M, Ellory JC. Inhibition of active chloride transport by piretanide. Nature 1978; 273: 678–680.
   PubMed Web of Science ®Google Scholar